Making her triumphant return to the show is Urvi Shah, MD, hem/onc and multiple myeloma expert at Memorial Sloan Kettering Cancer Center, this time to shed light on how dietary considerations present a low-risk way to modify the microbiome and help prevent cancer. She opines on whether her findings on the association between diet and cancer in myeloma will be scalable in other malignancies, offers a few of her findings related to dietary habits and cancer diagnoses, describes the double standard in the ways drug vs dietary clinical trials are considered, and shares a recent publication she published on the planetary impact of dietary choices, among other discussion points.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
